INCY - Incyte Corporation News

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

gurufocus.com

Incyte to Report Third Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results confe

businesswire.com

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--3Q26 Earnings Announcement.

If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized ba

globenewswire.com

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-Am

Stifel Maintains Buy on Incyte, Raises Price Target to $157

Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price targ

If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized ba

Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128

Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises t

INCY or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (IN

JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price

FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduc

prnewswire.com

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabet

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and o

HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and

businesswire.com

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult a

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval

RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and main

Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of D

Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Mul

businesswire.com

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Br

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Br

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostic

Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?

The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta

defenseworld.net

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte (NASDAQ: INCY) executives outlined a strategy centered on expanding its non-JAKAFI business,

prnewswire.com

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced

marketbeat.com

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, ad

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixe

Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transc

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak

defenseworld.net

Integrated Wealth Concepts LLC Sells 5,987 Shares of Incyte Corporation $INCY

Integrated Wealth Concepts LLC trimmed its holdings in Incyte Corporation (NASDAQ: INCY) by 26.0% du

INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-

Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized ba

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Tra

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?

Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise bi

Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized ba

Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152

Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy ratin

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130

Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises

Mizuho Maintains Outperform on Incyte, Raises Price Target to $137

Mizuho analyst Salim Syed maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price t

Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65

Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155

Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and raise

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First

MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemoth

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales gro

BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

Top 3 Health Care Stocks That May Implode This Month

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high

Barclays Maintains Overweight on Incyte, Raises Price Target to $139

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri